Ethinyl estradiol and norethindrone

Selected products prevent pregnancy in reproductive-age users. Nortrel contains norethindrone; Junel, Loestrin, Junel Fe 24 and Lo Loestrin Fe contain norethindrone acetate, which converts to norethindrone after absorption. This related pharmacology does not make their ingredient names, milligrams or pack schedules interchangeable. These are combined pills, not the norethindrone-only mini-pill or menopausal estradiol / norethindrone therapy.

No STI/HIV protection is provided; use appropriate barrier prevention. Lo Loestrin Fe and Junel Fe 24 safety/efficacy at BMI >35 kg/m² have not been evaluated; that evidence gap is not itself a label contraindication. This profile excludes triphasic, chewable and other estrogen/progestin products and does not establish pharmacy substitution or current stock availability.

EE means ethinyl estradiol. The Fe tablets are non-hormonal schedule aids, not therapeutic iron supplementation.

Junel / Loestrin / Nortrel labels provide Day-1 or Sunday starts; Sunday start requires backup through the first 7 active days. Junel Fe 24 provides Day-1/Sunday directions; Lo Loestrin Fe uses Day-1 start and 7-day backup for another starting day. Follow the exact switching instructions without an unintended gap. CDC 2024 permits initiation when reasonably certain not pregnant; starting >5 days after bleeding began requires 7-day backup. Product-specific directions may be more conservative.

For one late/missed hormonal pill with <48 hours elapsed, take promptly and continue; backup is generally unnecessary. For ≥2 consecutive missed hormonal pills (≥48 hours), take only the most recent missed pill, discard earlier missed pills, continue and use backup until 7 consecutive hormonal days. If missed near the hormone-free interval, omit that interval/start next pack. Consider emergency contraception after first-week misses with unprotected sex in the preceding 5 days; ulipristal requires different restart advice. This guidance concerns hormonal, not inert, pills.

Selected labels use their own instructions, sometimes different from CDC. Lo Loestrin Fe: one blue miss is taken promptly; two blue misses in weeks 1–2 use two tablets when remembered and two next day plus 7-day backup; two blue/white misses in weeks 3–4 or ≥3 hormonal misses require a new pack that day plus 7-day backup. Discard missed brown inert tablets without delaying the next pack. Junel Fe 24 and 21/7 labels have their own week/start-day rules. Do not combine label and CDC algorithms without a clinician / pharmacist plan. Vomiting/diarrhea within 3–4 hours follows the Lo Loestrin/Junel24 missed-dose instructions; prolonged illness needs backup review.

Modern Junel Fe 24/Lo Loestrin labels contraindicate smoking over35, high arterial/VTE risk (current/past DVT/PE, thrombophilia, coronary / cerebrovascular disease, thrombogenic cardiac disease), uncontrolled hypertension, vascular diabetes, specified migraine / focal-neurologic conditions, breast cancer history/current disease, liver disease/tumors, unexplained uterine bleeding and ombitasvir / paritaprevir / ritonavir ±dasabuvir. Exact older-label wording differs. CDC classifies migraine with aura at any age as category 4 (unacceptable risk); controlled hypertension or140–159/90–99 is category 3, ≥160/100 category 4. Do not infer that anticoagulation makes an estrogen pill automatically eligible.

Selected combined-pill labels carry a cigarette-smoking / cardiovascular warning: serious cardiovascular risk rises with smoking and age; women over35 who smoke should not use these products. Age alone is not the boxed contraindication. Modern label restrictions and CDC eligibility assessment both inform selection.

Common reported effects include nausea, headache, breast tenderness, bleeding changes/amenorrhea, mood symptoms and weight fluctuation; rates vary by product. Serious risks include thrombosis/arterial events, hypertension, liver complications and severe hypersensitivity / angioedema. Excess ingestion can cause nausea or withdrawal bleeding; seek medical/poison guidance, especially child ingestion, rather than assuming all pack ingredients are harmless.

Not every antibiotic is an enzyme inducer or requires backup. Use the exact interacting drug and current guidance rather than copying legacy broad antibiotic claims; vomiting/diarrhea is a separate absorption concern. No emergency-contraceptive pill-count conversion is supplied for these packs.

Stop contraception when pregnancy is confirmed; inadvertent early CHC exposure has not shown an increased birth-defect risk in cited epidemiology. Hormones / metabolites enter milk and combined pills may reduce milk production; selected modern labels advise another method while breastfeeding when possible. Balance maternal goals and feeding effects with postpartum eligibility; do not describe breastfeeding as a universal permanent contraindication.

CDC: CHCs are category 4 before 21 postpartum days. Nonbreastfeeding days 21–42: category 2 without VTE factors, category 3 (possibly4) with them; >42 category 1. Breastfeeding days 21–<30: category 3; days 30–42 category 2 without VTE factors, category 3 (possibly4) with them; >42 category 2. Selected product labels use no earlier than 4 weeks after delivery for nonbreastfeeding starts, requiring a product-specific plan. Obesity alone is category 2, but combined risk factors can make risk unacceptable; Junel24/LoLo BMI>35 evidence is absent.

Modern labels expect postpubertal adolescent efficacy similar to adults; before menarche and after menopause use is not indicated. Renal/hepatic PK studies are absent for Junel24/LoLo, and no renal-adjustment formula is provided. Liver contraindications matter more than lowering a dose. CDC classifies current nephrotic syndrome or dialysis as category 4; assess renal-associated vascular comorbidities. Choose another appropriate method when estrogen eligibility is poor.

Suppresses ovulation through gonadotropin effects, with cervical-mucus / endometrial changes also described in older labels. Norethindrone acetate rapidly deacetylates to norethindrone. EE-only Lo Loestrin tablets remain hormonally active; Fe tablets do not contribute contraception.

Absorption

Junel24 norethindrone/EE peaks1–4 hours; substantial first-pass metabolism.

Protein binding

Both steroids >95% bound; norethindrone binds albumin/SHBG, EE primarily albumin.

Metabolism / elimination

Extensive reduction/oxidation and sulfate/glucuronide conjugation; CYP3A4 contributes EE oxidation; metabolites excreted urine/feces.

Half-life examples

Junel24 steady-state norethindrone~8 hours / EE ~14; LoLo studies ~10/~16 hours. These are formulation-specific observations, not missed-pill grace periods.

• Measure BP before starting; follow BP and changing health/medicine risks during care.
• Review smoking, migraine/aura, VTE/cardiac history, postpartum status, liver/breast disease and exact pack/adherence.
• Assess new headache, bleeding changes, mood symptoms and glucose/lipid concerns when clinically indicated.
• A pelvic exam or routine thrombophilia / liver / glucose testing is not required solely to start CHCs in an otherwise healthy person under CDC guidance; investigate specific risks/symptoms.

• Take tablets in the exact pack order daily; know which are hormonal and when to start the next pack. Keep product-specific missed-pill/backup instructions available.
• These pills do not prevent STIs/HIV; discuss barrier protection. Do not smoke, and report major surgery/immobility or new migraine.
• Get urgent help for chest pain, breathing difficulty, unilateral leg swelling, sudden weakness / speech / vision change or severe new headache.
• Discuss emergency contraception promptly after risky misses, and confirm pregnancy when appropriate; do not delay the next pack merely waiting for bleeding.

Active tablets

24 light-yellow tablets: norethindrone acetate 1 mg / EE 20 mcg

Inactive tablets

4 brown tablets: ferrous fumarate 75 mg; no therapeutic iron purpose

Labeler / imprints

Teva Pharmaceuticals USA · active b/977; inert b/247

Example NDC

0093-5328-62 · three 28-tablet blister cards

See the dosage table for selected 10,20,30 and35 mcg EE schedules. LoLo includes two EE-only tablets; 21/7 packs and Junel24 do not. Nortrel has norethindrone, while listed Junel/Loestrin products have acetate. Do not assume triphasic, chewable, estrogen-only or progestin-only products follow these instructions. Verify the supplied label and available package.

Junel / Loestrin / Nortrel and Junel24:20–25°C; Junel24 explicitly protect from light. Lo Loestrin Fe:25°C, excursions15–30°C. Keep the original ordered blister and date/day labels so active/placebo sequence stays clear; keep out of children’s reach. A missed inert tablet should not extend the interval before the next pack.